Ulixertinib is under clinical development by BioMed Valley Discoveries and currently in Phase I for Neurofibromatoses Type I (Von Recklinghausen’s Disease).
Zig-Zag Sales in Q2 Grow 12% Sequentially to $46.7 Million
Turning Point Brands Announces Second Quarter 2023 Results; Increases 2023 Guidance Net Sales for Q2 2023 Zig-Zag and Stoker’s Products Increased 3.7 Percent Year-Over-Year Adjusted